 Michael Harris-Love
Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Muscle Strength | 14 | 2025 | 327 | 2.740 |
Why?
| | Myositis, Inclusion Body | 5 | 2015 | 11 | 1.440 |
Why?
| | Gait | 6 | 2025 | 315 | 1.400 |
Why?
| | Myositis | 8 | 2015 | 52 | 1.400 |
Why?
| | Ultrasonography | 4 | 2024 | 764 | 1.260 |
Why?
| | Knee Joint | 3 | 2025 | 412 | 0.960 |
Why?
| | Muscle, Skeletal | 11 | 2024 | 1750 | 0.890 |
Why?
| | Heel | 2 | 2014 | 9 | 0.850 |
Why?
| | Quadriceps Muscle | 3 | 2024 | 118 | 0.770 |
Why?
| | Dermatomyositis | 6 | 2022 | 23 | 0.760 |
Why?
| | Osteoarthritis, Knee | 2 | 2025 | 270 | 0.760 |
Why?
| | Lower Extremity | 3 | 2024 | 436 | 0.680 |
Why?
| | Multiple Sclerosis | 2 | 2024 | 468 | 0.680 |
Why?
| | Polymyositis | 5 | 2014 | 15 | 0.670 |
Why?
| | Exercise Therapy | 4 | 2013 | 450 | 0.630 |
Why?
| | Sarcoma, Kaposi | 2 | 2009 | 80 | 0.490 |
Why?
| | Physical Therapists | 1 | 2015 | 61 | 0.420 |
Why?
| | Isometric Contraction | 2 | 2013 | 184 | 0.410 |
Why?
| | Range of Motion, Articular | 2 | 2019 | 413 | 0.400 |
Why?
| | Ankle | 1 | 2013 | 61 | 0.400 |
Why?
| | Predictive Value of Tests | 5 | 2025 | 2072 | 0.330 |
Why?
| | Muscle Neoplasms | 1 | 2009 | 8 | 0.310 |
Why?
| | Skin Neoplasms | 2 | 2009 | 853 | 0.300 |
Why?
| | Arthralgia | 1 | 2009 | 57 | 0.290 |
Why?
| | Middle Aged | 17 | 2025 | 34597 | 0.290 |
Why?
| | Cross-Sectional Studies | 4 | 2025 | 5653 | 0.270 |
Why?
| | Friedreich Ataxia | 2 | 2009 | 78 | 0.270 |
Why?
| | Biomechanical Phenomena | 2 | 2025 | 838 | 0.260 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2024 | 623 | 0.250 |
Why?
| | Physicians | 1 | 2015 | 929 | 0.240 |
Why?
| | Aged | 11 | 2025 | 24798 | 0.230 |
Why?
| | Severity of Illness Index | 6 | 2014 | 2905 | 0.230 |
Why?
| | Male | 23 | 2025 | 70063 | 0.230 |
Why?
| | Humans | 34 | 2025 | 141267 | 0.220 |
Why?
| | Foot Diseases | 1 | 2004 | 18 | 0.210 |
Why?
| | Motor Activity | 2 | 2009 | 718 | 0.210 |
Why?
| | Muscle Weakness | 4 | 2013 | 94 | 0.200 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 2 | 2014 | 96 | 0.200 |
Why?
| | Weight-Bearing | 1 | 2004 | 174 | 0.200 |
Why?
| | Exercise Tolerance | 2 | 2009 | 281 | 0.190 |
Why?
| | Veterans | 2 | 2025 | 1521 | 0.190 |
Why?
| | Leg | 1 | 2004 | 238 | 0.190 |
Why?
| | Adult | 17 | 2024 | 39203 | 0.180 |
Why?
| | HIV Infections | 2 | 2009 | 2970 | 0.180 |
Why?
| | Activities of Daily Living | 2 | 2009 | 425 | 0.180 |
Why?
| | Resistance Training | 1 | 2024 | 168 | 0.170 |
Why?
| | Kinetics | 1 | 2025 | 1654 | 0.170 |
Why?
| | Female | 20 | 2024 | 75729 | 0.170 |
Why?
| | Bulbo-Spinal Atrophy, X-Linked | 2 | 2011 | 3 | 0.170 |
Why?
| | Physical Therapy Modalities | 1 | 2004 | 318 | 0.160 |
Why?
| | Dance Therapy | 1 | 2019 | 3 | 0.150 |
Why?
| | Immunosuppressive Agents | 2 | 2017 | 855 | 0.150 |
Why?
| | Video Games | 1 | 2019 | 28 | 0.150 |
Why?
| | Muscular Diseases | 2 | 2015 | 113 | 0.150 |
Why?
| | Hand Strength | 1 | 2018 | 132 | 0.140 |
Why?
| | Infliximab | 1 | 2017 | 111 | 0.130 |
Why?
| | Dermatologic Agents | 1 | 2017 | 70 | 0.130 |
Why?
| | Kidney Failure, Chronic | 1 | 2022 | 600 | 0.120 |
Why?
| | Hypertension | 1 | 2024 | 1253 | 0.110 |
Why?
| | International Cooperation | 1 | 2005 | 195 | 0.110 |
Why?
| | Exercise | 3 | 2024 | 2108 | 0.110 |
Why?
| | Reproducibility of Results | 5 | 2015 | 3343 | 0.110 |
Why?
| | Accidental Falls | 2 | 2014 | 213 | 0.100 |
Why?
| | Aging | 1 | 2024 | 1921 | 0.100 |
Why?
| | Quality of Life | 2 | 2009 | 3021 | 0.100 |
Why?
| | Terminology as Topic | 1 | 2004 | 244 | 0.090 |
Why?
| | Immunologic Factors | 1 | 2014 | 249 | 0.090 |
Why?
| | Azasteroids | 1 | 2011 | 5 | 0.090 |
Why?
| | Disease Management | 1 | 2005 | 632 | 0.090 |
Why?
| | Age Factors | 1 | 2018 | 3292 | 0.090 |
Why?
| | Clinical Trials as Topic | 1 | 2005 | 1036 | 0.080 |
Why?
| | Antirheumatic Agents | 1 | 2013 | 298 | 0.080 |
Why?
| | Patellofemoral Pain Syndrome | 1 | 2009 | 6 | 0.080 |
Why?
| | Ubiquinone | 1 | 2009 | 35 | 0.080 |
Why?
| | Antibodies, Neoplasm | 1 | 2009 | 33 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2014 | 1974 | 0.070 |
Why?
| | Analysis of Variance | 2 | 2008 | 1314 | 0.070 |
Why?
| | CD4 Lymphocyte Count | 1 | 2009 | 273 | 0.070 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2008 | 125 | 0.070 |
Why?
| | Muscle Stretching Exercises | 1 | 2008 | 19 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2005 | 1543 | 0.070 |
Why?
| | Child | 9 | 2022 | 22342 | 0.070 |
Why?
| | Viral Load | 1 | 2009 | 501 | 0.070 |
Why?
| | Treatment Outcome | 8 | 2017 | 11194 | 0.060 |
Why?
| | Radiography | 1 | 2009 | 847 | 0.060 |
Why?
| | Linear Models | 1 | 2008 | 855 | 0.060 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2007 | 129 | 0.060 |
Why?
| | Double-Blind Method | 3 | 2017 | 1980 | 0.060 |
Why?
| | Diagnosis, Differential | 1 | 2009 | 1493 | 0.060 |
Why?
| | Walkers | 1 | 2004 | 2 | 0.050 |
Why?
| | Lymphedema | 1 | 2004 | 24 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 2 | 2022 | 3731 | 0.050 |
Why?
| | Sickness Impact Profile | 1 | 2003 | 58 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2024 | 290 | 0.050 |
Why?
| | Task Performance and Analysis | 1 | 2004 | 196 | 0.050 |
Why?
| | Muscle Fatigue | 1 | 2003 | 97 | 0.050 |
Why?
| | Rituximab | 2 | 2014 | 205 | 0.050 |
Why?
| | Physical Fitness | 1 | 2003 | 206 | 0.050 |
Why?
| | Regional Blood Flow | 1 | 2024 | 498 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2009 | 1472 | 0.050 |
Why?
| | Disability Evaluation | 1 | 2003 | 303 | 0.050 |
Why?
| | Adolescent | 6 | 2013 | 22064 | 0.040 |
Why?
| | Follow-Up Studies | 3 | 2011 | 5213 | 0.040 |
Why?
| | Fatigue | 1 | 2022 | 338 | 0.040 |
Why?
| | Risk Factors | 1 | 2014 | 10482 | 0.040 |
Why?
| | Child, Preschool | 3 | 2009 | 11473 | 0.040 |
Why?
| | Cicatrix | 1 | 2009 | 69 | 0.040 |
Why?
| | Muscular Atrophy | 1 | 2009 | 87 | 0.040 |
Why?
| | Disease Progression | 2 | 2011 | 2798 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2024 | 1605 | 0.030 |
Why?
| | Independent Living | 1 | 2019 | 112 | 0.030 |
Why?
| | Calcinosis | 1 | 2009 | 238 | 0.030 |
Why?
| | Pilot Projects | 2 | 2017 | 1815 | 0.030 |
Why?
| | Biomarkers | 1 | 2008 | 4179 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2009 | 16373 | 0.030 |
Why?
| | Prednisone | 1 | 2017 | 228 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2017 | 773 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2017 | 577 | 0.030 |
Why?
| | Prognosis | 1 | 2003 | 4077 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 1042 | 0.030 |
Why?
| | Risk Assessment | 1 | 2003 | 3515 | 0.030 |
Why?
| | Muscle Contraction | 2 | 2008 | 435 | 0.020 |
Why?
| | Consensus | 1 | 2005 | 546 | 0.020 |
Why?
| | Incidence | 1 | 2009 | 2800 | 0.020 |
Why?
| | Placebos | 1 | 2013 | 195 | 0.020 |
Why?
| | Inflammation | 1 | 2024 | 2895 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2019 | 7947 | 0.020 |
Why?
| | Observer Variation | 2 | 2006 | 355 | 0.020 |
Why?
| | Dutasteride | 1 | 2011 | 5 | 0.020 |
Why?
| | Walking | 2 | 2009 | 541 | 0.020 |
Why?
| | Obesity | 1 | 2024 | 3001 | 0.020 |
Why?
| | Pain Measurement | 1 | 2013 | 553 | 0.020 |
Why?
| | Electrodiagnosis | 1 | 2009 | 16 | 0.020 |
Why?
| | Gait Apraxia | 1 | 2009 | 1 | 0.020 |
Why?
| | Erectile Dysfunction | 1 | 2009 | 39 | 0.020 |
Why?
| | Neural Conduction | 1 | 2009 | 90 | 0.020 |
Why?
| | Alemtuzumab | 1 | 2009 | 15 | 0.020 |
Why?
| | Peripheral Nerves | 1 | 2009 | 72 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2009 | 167 | 0.020 |
Why?
| | Lymphocyte Depletion | 1 | 2009 | 136 | 0.020 |
Why?
| | Glucocorticoids | 1 | 2013 | 533 | 0.020 |
Why?
| | Proprioception | 1 | 2008 | 27 | 0.020 |
Why?
| | Androgens | 1 | 2009 | 187 | 0.020 |
Why?
| | Age of Onset | 1 | 2009 | 534 | 0.020 |
Why?
| | Electromyography | 1 | 2009 | 411 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2007 | 201 | 0.020 |
Why?
| | Action Potentials | 1 | 2009 | 505 | 0.020 |
Why?
| | Autoantibodies | 1 | 2014 | 1474 | 0.020 |
Why?
| | Surveys and Questionnaires | 2 | 2009 | 5937 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2009 | 517 | 0.020 |
Why?
| | Testosterone | 1 | 2009 | 404 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 2007 | 417 | 0.010 |
Why?
| | Biopsy | 1 | 2009 | 1070 | 0.010 |
Why?
| | Fractures, Bone | 1 | 2011 | 406 | 0.010 |
Why?
| | Antioxidants | 1 | 2009 | 597 | 0.010 |
Why?
| | Recovery of Function | 1 | 2009 | 683 | 0.010 |
Why?
| | Physical Therapy Specialty | 1 | 2006 | 53 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2006 | 432 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2009 | 911 | 0.010 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2009 | 916 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2009 | 1113 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2007 | 2061 | 0.010 |
Why?
| | Physical Examination | 1 | 2003 | 242 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2009 | 2826 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2009 | 2608 | 0.010 |
Why?
| | Time Factors | 1 | 2009 | 6971 | 0.010 |
Why?
| | Exercise Test | 1 | 2000 | 623 | 0.010 |
Why?
|
|
Harris-Love's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|